Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nasal Steroids After FESS in CRSwNP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients who have had FESS for CRSwNP within the study period~Exclusion Criteria:~1. Patients who are under the age of 18~2. Concurrent oral corticosteroid use of the equivalent of greater than 10 mg of prednisone use per day~3. The use of medications that accelerate the clearance of systemic cortisol (Dilantin, rifampin, amphetamines, and lithium)~4. The use of medications that inhibit the clearance of systemic cortisol (ketoconazole, amphotericin B, bupropion, fluoroquinolones)~5. Known hypersensitivity to corticosteroids~6. A personal history of Wegener's Granulomatosis or other autoimmune disease with nasal manifestations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone nasal spray (Type: ACTIVE_COMPARATOR): Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
- budesonide respule in head upright (Type: ACTIVE_COMPARATOR): Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
- budesonide head forward (Type: ACTIVE_COMPARATOR): Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.

Based on this trial design, predict the completion outcome and termination type (if applicable).